High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging

Sha Lou; Benjamin Balluff; Marieke A. de Graaff; Arjen H. G. Cleven; Inge Briaire-de Bruijn; Judith V. M. G. Bovee; Liam A. McDonnell

doi:10.1002/pmic.201500514

High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging

Sha Lou, Benjamin Balluff, Marieke A. de Graaff, Arjen H. G. Cleven, Inge Briaire-de Bruijn, Judith V. M. G. Bovee, Liam A. McDonnell^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high-grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDIMSI of proteins to distinguish between high-grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (N-total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p

Original language	English
Pages (from-to)	1802-1813
Journal	Proteomics
Volume	16
Issue number	11-12
DOIs	https://doi.org/10.1002/pmic.201500514
Publication status	Published - Jun 2016

Keywords

Biomarker discovery
Biomedicine
Intratumor heterogeneity
Mass spectrometry imaging
Soft tissue sarcoma

Access to Document

10.1002/pmic.201500514

Cite this

@article{1ad9765d7b654dcdaa08a5e296c38eb6,

title = "High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging",

abstract = "The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high-grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDIMSI of proteins to distinguish between high-grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (N-total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p ",

keywords = "Biomarker discovery, Biomedicine, Intratumor heterogeneity, Mass spectrometry imaging, Soft tissue sarcoma",

author = "Sha Lou and Benjamin Balluff and {de Graaff}, {Marieke A.} and Cleven, {Arjen H. G.} and {Briaire-de Bruijn}, Inge and Bovee, {Judith V. M. G.} and McDonnell, {Liam A.}",

year = "2016",

month = jun,

doi = "10.1002/pmic.201500514",

language = "English",

volume = "16",

pages = "1802--1813",

journal = "Proteomics",

issn = "1615-9853",

publisher = "Wiley-VCH Verlag",

number = "11-12",

}

TY - JOUR

T1 - High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging

AU - Lou, Sha

AU - Balluff, Benjamin

AU - de Graaff, Marieke A.

AU - Cleven, Arjen H. G.

AU - Briaire-de Bruijn, Inge

AU - Bovee, Judith V. M. G.

AU - McDonnell, Liam A.

PY - 2016/6

Y1 - 2016/6

N2 - The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high-grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDIMSI of proteins to distinguish between high-grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (N-total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p

AB - The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high-grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDIMSI of proteins to distinguish between high-grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (N-total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p

KW - Biomarker discovery

KW - Biomedicine

KW - Intratumor heterogeneity

KW - Mass spectrometry imaging

KW - Soft tissue sarcoma

U2 - 10.1002/pmic.201500514

DO - 10.1002/pmic.201500514

M3 - Article

C2 - 27174013

SN - 1615-9853

VL - 16

SP - 1802

EP - 1813

JO - Proteomics

JF - Proteomics

IS - 11-12

ER -